NSCLC represents the predominant subtype of lung cancer, which remains the leading cause of cancer-related mortality globally. Surgery remains the cornerstone treatment modality for patients presenting with localized or locally advanced non-metastatic disease, notably stages I to IIIA. However, the specifics regarding which surgical techniques yield optimal survival benefits, alongside epidemiological trends reflecting broader shifts in clinical practice, have remained inadequately characterized in large populations—until now.

The study harnessed the richness of the French National Hospitalization Database (PMSI), encompassing a vast cohort of patients who underwent their first lung resection between 2015 and 2019. By focusing exclusively on patients with non-metastatic NSCLC, the investigators provided a finely calibrated window into the nuanced strategies employed across national centers and how these translate into long-term patient outcomes. This kind of real-world evidence is crucial, given that randomized controlled trials may not fully capture the diversity of clinical practice and patient variability seen in routine care.

Remarkably, the data illuminated a consistent annual increase of 4.5% in the rate of lung resections performed for non-metastatic NSCLC over the five-year period. This uptick might reflect earlier diagnosis patterns, improved referral pathways, or a growing acceptance of surgical intervention as part of a multimodal approach to localized lung cancer. It also underscores the urgent need to continuously refine surgical decision-making parameters to optimize patient survival.

One of the most striking trends noted was a shift toward more conservative and minimally invasive surgical techniques. Lobectomy emerged as the dominant procedure, increasing from 79.8% to 84.9% of cases over the studied period. Concurrently, the adoption of video-assisted thoracoscopic surgery (VATS), a less invasive approach allowing for reduced postoperative morbidity and faster recovery, nearly doubled—from 29.6% to 46.4%. These shifts are indicative of a paradigm move toward balancing oncological control with maximizing preservation of lung function.

The survival analyses yield sobering, yet informative results concerning the prognostic implications of resection type. Five-year disease-free survival (DFS), which encompasses the time until recurrence or death, was notably superior following lobectomy—standing at 52.3%, compared to 33.7% for infralobar resections, 42.3% after bilobectomy, and only 33.6% after pneumonectomy. These figures provide compelling evidence that more extensive resections, often necessitated by advanced local disease, are associated with comparatively poorer survival.

Similarly, overall survival (OS) metrics resonated with this pattern. Patients undergoing lobectomy enjoyed a five-year OS of 70.2%, substantially higher than the 58.4%, 59.3%, and 46.3% observed for infralobar resections, bilobectomy, and pneumonectomy respectively. These survival disparities emphasize the prognostic significance of surgical extent, likely reflecting tumor burden as well as physiological impact of larger resections on patient resilience.

The study’s comprehensive approach highlights the utility of surgical type as an indirect but robust marker of disease extent, with more conservative surgeries aligning with less advanced disease and better outcomes. This notion places surgical decision-making as a sentinel point in multidisciplinary lung cancer care, guiding prognosis and adjunctive treatment planning.

Beyond the numbers, this research underscores a transformation in thoracic oncology surgery, moving steadily toward less invasive and lung-sparing techniques without compromising oncological safety. The evolution of VATS and other minimally invasive strategies represents a pivotal advancement, affording patients reduced postoperative pain, lower complications, and shorter hospital stays—elements that contribute to enhanced quality of life and perhaps bolster long-term survival through improved recovery.

The reliance on nationwide claims data, with its granularity and real-world scope, addresses a critical gap in lung cancer research. Clinical trials, while essential, often have restrictive inclusion criteria that can exclude older or comorbid patients commonly seen in everyday practice. These findings thus carry high external validity, resonating with the realities faced by clinicians in diverse healthcare settings.

Moreover, the trends described could inform health policy aimed at resource allocation and surgical training, ensuring that the proliferation of minimally invasive techniques aligns with best patient outcomes nationwide. Stakeholders might leverage these insights to optimize referral practices, expand access to VATS, and ensure that surgical expertise corresponds with the rising case volume.

Notably, the retrospective design, while powerful, is inherently constrained by the quality and completeness of administrative datasets. However, the large sample size spanning multiple years boosts confidence in the reliability and representativeness of the results. Further studies are warranted to integrate molecular tumor profiles, perioperative systemic therapies, and patient-reported outcomes to enrich the prognostic narrative.

This study also calls into question the role of pneumonectomy and extensive resections in modern lung cancer surgery, given their association with lower survival rates. It highlights the need for patient selection criteria refinement and potentially increased utilization of neoadjuvant therapies to downstage tumors and allow for more conservative resections.

The increasing rate of surgical interventions aligns intriguingly with concurrent advances in lung cancer screening and imaging, which may be detecting smaller, earlier-stage tumors more amenable to surgery. As lung cancer screening programs expand globally, real-world studies such as this provide a benchmark for expected shifts in treatment patterns and outcomes.

In sum, this landmark investigation presents a compelling narrative of surgical evolution in resected non-metastatic NSCLC, blending epidemiological rigor with clinical nuance. The findings harness real-world data to clarify the impact of different surgical interventions on survival outcomes and affirm the growing importance of minimally invasive, lung-preserving procedures.

As lung cancer management continues to integrate immunotherapies and targeted treatments, the surgical dimension remains pivotal. This study sets the stage for future multidisciplinary strategies that synergize cutting-edge systemic therapies with optimized surgical care, ultimately enhancing long-term survival and quality of life for patients battling NSCLC.

Subject of Research: Epidemiology, surgical management, and survival outcomes in patients with resected non-metastatic non-small cell lung cancer.

Article Title: Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study.

Article References:
Renaud, S., Casabianca, P., Diez-Andreu, P. et al. Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study. BMC Cancer 25, 966 (2025). https://doi.org/10.1186/s12885-025-14334-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14334-2

Heart failure is characterized by the heart’s impaired ability to maintain adequate blood flow and pressure, a chronic condition that typically lacks a definitive cure but can be managed effectively with appropriate therapies. The study, spearheaded by French investigators led by Dr. Guillaume Baudry and Professor Nicolas Girerd from Nancy University Hospital, delves into the patterns of cardiologist engagement and their association with patient survival across an unprecedented nationwide cohort exceeding 650,000 individuals diagnosed within five years prior to January 2020.

Utilizing comprehensive French national medical administrative databases, the investigators stratified heart failure patients by recent hospitalization history and diuretic therapy usage—two clinically expedient markers of disease severity and fluid overload. The analytical framework was designed to uncover whether cardiologist follow-up frequency impacted all-cause mortality and hospital readmission rates within a subsequent year, and to pinpoint optimal consultation intervals tailored to risk profiles.

The stark findings reveal that approximately 40% of heart failure patients nationwide do not receive any cardiologist consultation within a year, a sobering insight given that survivors who had at least yearly cardiology follow-up exhibited a 24% reduction in mortality risk. This inverse relationship between specialist care and death reinforces the clinical imperative for routine cardiology involvement, positioning it as a potentially life-saving intervention rather than a discretionary referral.

Crucially, the study presents a nuanced, risk-adapted model that recommends differentiated follow-up frequencies. Patients without recent hospitalization and not receiving diuretics—a subgroup with relatively stable hemodynamics—benefited optimally from a single cardiologist visit annually, halving their one-year mortality risk from 13% to 6.7%. This suggests that even “stable” patients derive substantial survival advantage from specialist surveillance.

Conversely, those using diuretics without recent hospitalization—indicative of ongoing volume management needs—fared best with two to three cardiology appointments per year, reducing mortality from 21.3% to 11.9%. This increased frequency likely facilitates timely therapy adjustment responsive to evolving clinical status. Additionally, patients with hospitalizations in the preceding five years but not the last year similarly required biannual to triannual follow-up to halve their risk from 24.8% to 12.9%.

For the highest risk group—those hospitalized within the past year—the data underscored the necessity of more intensive scrutiny, with quarterly cardiologist consultations lowering mortality from an alarming 34.3% to 18.2%. These findings articulate a clear directive that recent acute decompensation predicates a more aggressive follow-up schedule to mitigate fatal outcomes.

Despite the compelling associations demonstrated, the research team prudently acknowledges inherent limitations of retrospective observational design. While cardiologist involvement correlates robustly with improved survival and fewer hospitalizations, causality cannot be firmly established. Confounding variables or unmeasured factors could influence these relationships; for example, patients under cardiology care may inherently possess better overall access to healthcare resources or adherence to guideline-directed medical therapies.

Nevertheless, the investigators emphasize the practical utility of the two simple clinical criteria—recent hospitalization and diuretic use—as scalable tools to stratify patient risk without reliance on costly or complex diagnostics. This pragmatic approach holds promise for widespread application, particularly in resource-limited settings where optimizing specialty referrals could yield pronounced public health benefits.

The study also highlights concerning disparities in cardiologist access, noting that women and older patients, as well as those with concurrent chronic conditions like diabetes and pulmonary diseases, are less frequently engaged by cardiology services. Such inequities mirror global patterns and suggest systemic barriers that must be addressed to ensure equitable care delivery.

In an accompanying editorial, Professor Lars Lund of the Karolinska Institutet contextualized these findings within a broader clinical conundrum: Despite decades of scientific breakthroughs heralding effective heart failure therapies, real-world implementation lag persists. He underscored the paradox of patients being diverted away from cardiology follow-up towards overtaxed primary care providers, often unable to navigate the intricacies of advanced heart failure management.

Professor Lund’s commentary reinforces the notion that specialty follow-up is not merely an administrative luxury but an essential pillar of achieving optimal outcomes. The study invigorates calls for revising care pathways to embed systematic cardiology referral, akin to oncology’s standard referral practices, thereby closing the gap between evidence and practice.

Future directions, as outlined by the French research team, include prospective interventional trials to rigorously test the causative impact of varying cardiology follow-up intensities and exploration of cardiologist engagement effects across diverse international healthcare systems. Such studies will be pivotal in refining guidelines and influencing health policy worldwide.

Further emphasizing the complexity of heart failure management, subsequent analyses from the same cohort unveiled sex-related disparities in healthcare utilization and outcomes. Women were notably less likely to be prescribed RAS inhibitors—cornerstone medications that modulate blood pressure and improve cardiovascular prognosis—yet paradoxically demonstrated better survival and fewer heart failure events than men. These nuanced insights beckon further research to unravel biological and sociocultural factors underpinning sex differences in heart failure trajectories.

In summary, this comprehensive nationwide cohort study presents compelling evidence that cardiologist involvement confers substantial mortality and morbidity benefits for heart failure patients, with a clear gradient of follow-up intensity tailored to recent clinical events and therapeutic markers. The findings challenge healthcare systems to adopt more systematic referral algorithms and reduce present disparities in specialist care access, heralding a new paradigm emphasizing targeted, risk-adapted specialist engagement as cornerstone of heart failure management.

Subject of Research: People

Article Title: Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort

News Publication Date: 18-May-2025

Web References:
10.1093/eurheartj/ehaf218

References:

1. Baudry G, Girerd N, et al. Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort. European Heart Journal 2025. DOI: 10.1093/eurheartj/ehaf218.
2. Editorial by Lars Lund, Karolinska Institutet, Stockholm, Sweden, European Heart Journal 2025.
3. Heart Failure Congress 2025 presentations on the same cohort.

Keywords: Heart failure, Heart disease, Cardiovascular disorders, Cardiology, Mortality rates

Achieving ELITE Status requires rigorous demonstration of superior clinical outcomes through a comprehensive set of validated, risk-adjusted metrics that benchmark a program’s performance against national peers. The INTERLINK Performance Model evaluates numerous factors including patient survival rates, graft function longevity, post-transplant complications, and adherence to evidence-based protocols to ensure only the most effective programs receive this distinction. Ochsner’s elevated scoring not only reflects technical excellence in surgical procedures but also highlights the program’s robust patient management strategies and commitment to continuous quality improvement.

Dr. Ari Cohen, director of the Ochsner Transplant Institute, attributes this milestone to the collective commitment of a diverse team of specialists who coordinate care seamlessly. “Transplant medicine demands a high level of integration among surgeons, nephrologists, coordinators, nurses, pharmacists, and social workers,” he stated. The transplantation process encompasses far more than the operative phase; it begins with thorough patient evaluation, immunological testing, and optimization of medical comorbidities, and extends into lifelong post-transplant monitoring to mitigate rejection and infection risks.

Ochsner’s kidney transplant journey dates back nearly five decades to 1973, marking the institution as an early adopter of transplant technology and protocols. Over the ensuing 52 years, the program has evolved alongside significant advances in immunosuppressive therapies, surgical techniques, and patient selection algorithms, culminating in more than 3,500 successful kidney and kidney-pancreas transplants. The longitudinal experience offers invaluable data supporting continuous innovation, whereby emerging techniques like minimally invasive donor nephrectomy and enhanced HLA matching algorithms have been implemented in clinical practice.

Central to the program’s success is its multidisciplinary transplant team, which leverages a wide spectrum of expertise. Transplant nephrologists play a critical role in pre- and post-transplant care, managing complex immunosuppressive regimens and surveillance for allograft rejection. Surgeons employ refined microsurgical approaches to minimize ischemia times and optimize vascular anastomoses, directly impacting graft viability. Pharmacists ensure tailored immunosuppressant dosing by monitoring drug levels and preventing adverse reactions, while social workers and coordinators address psychological and logistical barriers, thereby improving adherence and access to care.

The kidney transplant procedure itself involves the intricate surgical removal and implantation of the donor organ, ensuring vascular and urinary tract reconnections under sterile conditions that minimize ischemic injury. Advances, such as hypothermic machine perfusion and normothermic regional perfusion technologies, have further enhanced graft preservation and function, thereby increasing transplant success rates. Moreover, immunological innovations including desensitization protocols have expanded donor-recipient compatibility, enabling highly sensitized patients to access transplantation more readily.

Immunosuppressive management represents a cornerstone of transplant success. Therapies combining calcineurin inhibitors, antimetabolites, and corticosteroids are carefully balanced to prevent organ rejection while reducing infection susceptibility and other adverse effects. The Ochsner team employs sophisticated monitoring, including donor-specific antibody assays and protocol biopsies, ensuring early detection of complications and prompting timely intervention. Their patient-centered approach emphasizes individualized regimens based on pharmacogenomics and evolving immune profiles.

Looking ahead, Ochsner’s kidney transplant program continues to integrate cutting-edge research with clinical care. Current investigations into tolerance induction, aiming to retrain the recipient’s immune system to accept the transplanted organ without lifelong immunosuppression, hold promise for transforming transplant medicine. Additionally, the incorporation of digital health tools enables remote monitoring and enhanced patient engagement, improving long-term outcomes and quality of life for transplant recipients.

Ochsner Health, serving the Gulf South region with a vast network of 46 hospitals and over 370 clinics, leverages its extensive resources to ensure accessibility to expert transplant care. Its recognition by INTERLINK COE Networks & Programs not only underscores Ochsner’s clinical excellence but also serves as a benchmark for other institutions aspiring to improve transplant outcomes through innovation and multidisciplinary collaboration. Such accolades contribute to the ongoing elevation of transplant standards nationwide.

In summary, the attainment of ELITE Status by the Ochsner kidney transplant program exemplifies an exceptional balance of surgical expertise, innovative care models, and holistic patient management. It reflects decades of accumulated knowledge and experience, now recognized at the highest national level. This achievement reaffirms Ochsner Health’s commitment to delivering transformative organ transplant care that can significantly impact lives, reduce morbidity, and extend longevity for patients with end-stage renal disease.

For those seeking more details on Ochsner’s transplant services or interested in the latest advancements in renal transplantation care, the Ochsner Transplant Institute provides extensive resources and support via their comprehensive website. This center’s model of excellence sets a new paradigm for what is possible in organ transplantation, intertwining scientific rigor with compassionate care.

Subject of Research: Kidney transplantation program quality and outcomes at Ochsner Health

Article Title: Ochsner Health’s Kidney Transplant Program Awarded ELITE Status by INTERLINK COE Networks

News Publication Date: Not specified in the source content

Web References:

• https://www.ochsner.org/services/organ-transplants
• https://interlinkhealth.com/
• https://www.ochsner.org/

Keywords: Organ transplantation, kidney transplant, transplant outcomes, ELITE Status, Ochsner Health, multidisciplinary transplant team, immunosuppression, graft survival, transplant innovation